Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Do stress hormones influence choice? A systematic review of pharmacological interventions on the HPA axis and/or SAM system.Social cognitive and affective neuroscience · 2024Pooled it
- Risky decision-making in the balloon analogue risk task - the role of noradrenaline and cortisol.Psychopharmacology · 2026Trial
- Dissociable glucocorticoid and noradrenergic effects on parochial cooperation and competition in intergroup conflict.Proceedings of the National Academy of Sciences of the United States of America · 2025Trial
- Does testosterone impair men's cognitive empathy? Evidence from two large-scale randomized controlled trials.Proceedings. Biological sciences · 2019Trial
- Basal cortisol level modulates stress-induced opioid-seeking behavior.Neurobiology of stress · 2024Article
- Decision-making under stress: A psychological and neurobiological integrative model.Brain, behavior, & immunity - health · 2024Article
- Noradrenergic modulation of stress induced catecholamine release: Opposing influence of FG7142 and yohimbine.bioRxiv : the preprint server for biology · 2024Article
- Acute stress promotes effort mobilization for safety-related goals.Communications psychology · 2024Article
- COVID-19 stressor reduces risk taking: the role of trait interoception.Cognitive processing · 2023Article
- The Effects of Citalopram and Thalamic Dopamine DPsychiatry journal · 2022Article
- Risk sensitivity and theory of mind in human coordination.PLoS computational biology · 2021Article
- Genetic underpinnings of risky behaviour relate to altered neuroanatomy.Nature human behaviour · 2021Article
- Predicting the behavioural tendency of loss aversion.Scientific reports · 2019Article
- Testosterone, Cortisol and Financial Risk-Taking.Frontiers in behavioral neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss aversion is a well-known behavioral regularity in financial decision making, describing humans' tendency to overweigh losses compared to gains of the same amount. Recent research indicates that stress and associated hormonal changes affect loss aversion, yet the underlying neuroendocrine mechanisms are still poorly understood. Here, we investigated the causal influence of two major stress neuromodulators, cortisol and noradrenaline, on loss aversion during financial decision making. In a double-blind, placebo-controlled between-subject design, we orally administered either the α2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy young men. We tested the treatments' influence on a financial decision-making task measuring loss aversion and risk attitude. We found that both drugs combined, relative to either drug by itself, reduced loss aversion in the absence of an effect on risk attitude or choice consistency. Our data suggest that concurrent glucocorticoid and noradrenergic activity prompts an alignment of reward- with loss-sensitivity, and thus diminishes loss aversion. Our results have implications for the understanding of the susceptibility to biases in decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.